Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Salvador Martinez-Bartolome, James Sorrentino, Mahan Abbasian, Antonius Koller, Samanta Catueno, Brandon Brown, Yihua Qiu, Pilgrim Jackson, Steven Kornblau

Blood (2025) 146 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2025-3507

Published: 2025

Journal Articles

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2025-3494

Published: 2025

Journal Articles

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Steven Kornblau, Eduardo de Camargo Magalhaes, Brandon Brown, Samanta Catueno, Yihua Qiu, Courtney DiNardo, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2025-3492

Published: 2025

Journal Articles

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5271.

https://doi.org/10.1182/blood-2025-5271

Published: 2025

Journal Articles

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Ian Bouligny, Abhishek Maiti, Courtney DiNardo, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5270.

https://doi.org/10.1182/blood-2025-5270

Published: 2025

Journal Articles

Protein expression signatures reveal age-specific risk patterns in B-ALL

Samanta Catueno, Yihua Qiu, Gaye Jenkins, Eduardo de Camargo Magalhaes, Brandon Brown, Rebecca Garris, Branko Cuglievan, Elias Jabbour, Nicholas Short, Terzah Horton, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2025-1593

Published: 2025

Journal Articles

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Mathilde Poplineau, Steven Kornblau

Blood (2025) 146 (Supplement 1): 5259.

https://doi.org/10.1182/blood-2025-5259

Published: 2025

Journal Articles

High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

Steven Kornblau, Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Abhishek Maiti, Tapan Kadia

Blood (2025) 146 (Supplement 1): 5258.

https://doi.org/10.1182/blood-2025-5258

Published: 2025

Journal Articles

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Eduardo de Camargo Magalhaes, Samanta Catueno, Brandon Brown, Yihua Qiu, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2025-1700

Published: 2025

Journal Articles

Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing

Eduardo Sabino De Camargo Magalhaes, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2024) 144 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2024-208114

Published: 2024

Journal Articles

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Blood (2024) 144 (Supplement 1): 53.

https://doi.org/10.1182/blood-2024-211997

Published: 2024

Journal Articles

Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics

Eduardo Sabino De Camargo Magalhaes, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2024) 144 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2024-204068

Published: 2024

Journal Articles

Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics

Eduardo Sabino Magalhaes, Stefan Hubner, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2023) 142 (Supplement 1): 165.

https://doi.org/10.1182/blood-2023-186508

Published: 2023

Journal Articles

Proteomic Profiling Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients

Eduardo Sabino de Camargo Magalhaes, Stefan Hubner, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2023) 142 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2023-186723

Published: 2023

Journal Articles

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2023-186947

Published: 2023

Journal Articles

Proteomics-Based Strategy for the Recommendation of Conventional Chemotherapy Vs Venetoclax Plus Hypomethylating Agents in Adult Acute Myeloid Leukemia (AML)

Eduardo Sabino de Camargo Magalhaes, Brandon D Brown, Stefan Hubner, Yihua Qiu, Steven M. Kornblau

Blood (2022) 140 (Supplement 1): 6312–6313.

https://doi.org/10.1182/blood-2022-165158

Published: 2022

Journal Articles

RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome

Fieke W Hoff, Lourdes Sriraja, Yihua Qiu, Gaye Jenkins, Andrew Ligeralde, David T. Teachey, Brent L. Wood, Meenakshi Devidas, Mignon L. Loh, Todd A. Alonzo, Amina A Qutub, Evangelia Petsalaki, Steven M. Kornblau, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 6352–6353.

https://doi.org/10.1182/blood-2022-163881

Published: 2022

Journal Articles

Epigenetic Landscape Predicts Overall Survival and Remission Duration in Adult Acute Myeloid Leukemia

Eduardo Sabino de Camargo Magalhaes, Yihua Qiu, Steven M. Kornblau

Blood (2022) 140 (Supplement 1): 6331–6332.

https://doi.org/10.1182/blood-2022-169962

Published: 2022

Journal Articles

Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)

Stefan Hubner, Marina Konopleva, Zhihong Zeng, Fieke W Hoff, Yihua Qiu, Vivian Ruvolo, Terzah M. Horton, Steven M. Kornblau

Blood (2022) 140 (Supplement 1): 6260–6261.

https://doi.org/10.1182/blood-2022-163664

Published: 2022

Journal Articles

Protein Expression Signatures Predict Response, Relapse, and Survival after Venetoclax Containing Therapy in Adults with Acute Myeloid Leukemia

Brandon Brown, Yihua Qiu, Fieke W Hoff, Steven M. Kornblau

Blood (2021) 138 (Supplement 1): 227.

https://doi.org/10.1182/blood-2021-153906

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status

Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Protein expression signatures reveal age-specific risk patterns in B-ALL

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics

Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics

Proteomic Profiling Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Proteomics-Based Strategy for the Recommendation of Conventional Chemotherapy Vs Venetoclax Plus Hypomethylating Agents in Adult Acute Myeloid Leukemia (AML)

RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome

Epigenetic Landscape Predicts Overall Survival and Remission Duration in Adult Acute Myeloid Leukemia

Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)

Protein Expression Signatures Predict Response, Relapse, and Survival after Venetoclax Containing Therapy in Adults with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only